- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03962621
A Study of the Efficacy of Erbium:YAG 2940nm in Combination With 1064nm Laser on Facial Rejuvenation
May 22, 2019 updated by: xjpfW
A Randomized Controlled Trial of the Efficacy of a Non-ablative Erbium:YAG 2940nm in Combination With 1064nm Laser on Facial Rejuvenation
- Facial aging is a progressive, multifactor-induced and multidimensional process which is naturally irreversible. The prominent clinical features of skin aging include loss of volume, pigmentation irregularity, low light reflectance, static and dynamic wrinkles, etc.
- The development of superpulsed CO2 and Erbium: YAG 2940 nm resurfacing lasers was considered as the "gold standard" for the treatment of facial aging [8,9]. However, many drawbacks including intraoperative pain, post procedural erythema, edema, high risk of changes of pigmentation and long downtime have drawn concerns to patients and practitioners. Therefore, the facial rejuvenation therapies based on combined modalities to target various factors simutaneously have raised more and more interests.
- The Fotona 4D laser platform incorporates the long pulsed 1064 nm and 2940 nm lasers, which provides versatile modalities to target various skin aging problems simultaneously. The 1064 nm laser can penetrate deep into the skin to explode pigment particles, destroy blood vessels and heat the dermal collagen by targeting melanin and haemoglobin. The 2940 nm Er:YAG laser in Fotona 4D system integrates a non-ablative Smooth® mode and cold peel SupErficial™ mode. the half-face treated by a 2940 nm laser alone showed a significant improvement on indexes of skin wrinkles, texture, pores and elasticity as compared to the baseline.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients ranged in age from 35 to 60 years old.
- Patients had Dover scale between 2-4
- Fitzpatrick wrinkles scale between 1-3
- medium to very severe nasolabial fold depression with morphological scores of 2 - 3 points.
Exclusion Criteria:
- pregnancy,
- liver or kidney functional abnormality,
- skin ulceration
- skin cancer
- coagulation disorders
- patients on drugs of photosensitizing or anticoagulation agents
- systemic diseases such as cardiovascular disease, epilepsy, diabetes.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: 2940 nm group
Subjects were randomly assigned into two groups (n=10 per group) based on a treated with a Fotona 4D 2940 nm laser alone, the other side of face was treated with a Fotona 4D 2940 nm in combination with 1064 nm laser.
The patients received three treatment sessions with monthly intervals between each session.
|
Er:YAG 2940nm have been considered as a good treatment of facial aging, especially in wrinkles.(1)
Smooth®: 9-10 J/cm2, 7mm spot size, which is sequentially delivered to upper and lower labial mucosa and buccal mucosa to unilaterally accumulate 5000 shots; (2) SupErficial™: 0.5-1.0
J/cm2, 7mm spot size, a single pass
|
|
Active Comparator: 1064 nm group
Subjects were randomly assigned into two groups (n=10 per group) based on a treated with a Fotona 4D 1064 nm laser alone, the other side of face was treated with a Fotona 4D 2940 nm in combination with 1064 nm laser.
The patients received three treatment sessions with monthly intervals between each session.
|
The 1064 nm laser can penetrate deep into the skin to explode pigment particles, destroy blood vessels and heat the dermal collagen by targeting melanin and haemoglobin.(1)
Frac3®: 30-35 J/cm2, 1.6 ms pulse width, 4mm spot size, unilaterally accumulated 2000 shots; and (2) PIANO®: 160 J/cm2, 5s pulse width, spot size 9mm, unilaterally accumulated 20000 shots, to increase and maintain facial skin temperature to 39-40oC.
|
|
Experimental: Combined treatment group
Subjects were randomly assigned into two groups (n=10 per group) based on a treated with a Fotona 4D 2940 nm or 1064 nm laser (Fotona, Slovenia, EU) alone, the other side of face was treated with a Fotona 4D 2940 nm in combination with 1064 nm laser.
The patients received three treatment sessions with monthly intervals between each session.
|
Er:YAG 2940nm have been considered as a good treatment of facial aging, especially in wrinkles.(1)
Smooth®: 9-10 J/cm2, 7mm spot size, which is sequentially delivered to upper and lower labial mucosa and buccal mucosa to unilaterally accumulate 5000 shots; (2) SupErficial™: 0.5-1.0
J/cm2, 7mm spot size, a single pass
The 1064 nm laser can penetrate deep into the skin to explode pigment particles, destroy blood vessels and heat the dermal collagen by targeting melanin and haemoglobin.(1)
Frac3®: 30-35 J/cm2, 1.6 ms pulse width, 4mm spot size, unilaterally accumulated 2000 shots; and (2) PIANO®: 160 J/cm2, 5s pulse width, spot size 9mm, unilaterally accumulated 20000 shots, to increase and maintain facial skin temperature to 39-40oC.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visia CR imaging system
Time Frame: change from week0 to week24
|
With fast capture times and lighting modes designed to enhance the visualization of skin features, VISIA®-CR (Canfield Scientific, Inc. USA) is the standard in repeatable clinical imaging.
Visia CR imaging system can be used to assess the skin wrinkles, and elasticity
|
change from week0 to week24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Multiprobe skin testing system
Time Frame: change from week0 to week24
|
Multiprobe skin testing system (CK, Germany) is used to detect skin elasticity
|
change from week0 to week24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Gang Wang, Prof, Dermatology Derpartment of Xijing Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2017
Primary Completion (Actual)
January 1, 2019
Study Completion (Actual)
January 1, 2019
Study Registration Dates
First Submitted
May 10, 2019
First Submitted That Met QC Criteria
May 22, 2019
First Posted (Actual)
May 24, 2019
Study Record Updates
Last Update Posted (Actual)
May 24, 2019
Last Update Submitted That Met QC Criteria
May 22, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- XijingH-PF-20161117
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Facial Rejuvenation
-
Mesoestetic Pharma Group S.L.CompletedFacial RejuvenationBulgaria
-
NYU Langone HealthCompleted
-
Cynosure, Inc.CompletedFacial RejuvenationUnited States
-
Mesoestetic Pharma Group S.L.Opera CRO, a TIGERMED Group CompanyCompletedFacial RejuvenationRomania
-
Dr. Joseph M Novoa LibermannCg Bio Co., Ltd.RecruitingNasolabial Fold Correction | Wrinkles Such as Nasolabial Folds | Skin Rejuvenation | Facial AgingUnited Kingdom
-
DeNova ResearchCompletedFacial Rejuvenation With Neurotoxins and/or Hyaluronic Acid FillersUnited States
-
DeNova ResearchCompletedSubjects Requesting and Requiring Facial Rejuvenation With Neurotoxins and/or Hyaluronic Acid FillersUnited States
-
Acorn Biolabs Inc.RecruitingRejuvenation | Stem Cell | Facial Aging | Stem Cell BankingUnited States
-
Semikal TechnologyActive, not recruitingPeriorbital Wrinkles | Nasolabial Fold Correction | Volume Defects in the Mid-face | Skin Rejuvenation | Marionette Lines | Facial Aging | Lip Augmentation and Correction of Perioral Rhytids | Facial Wrinkles and Rhytides ReductionTurkey (Türkiye)
-
COR clinic of Regenerative MedicineCompleted
Clinical Trials on Fotona 4D 2940 nm laser
-
Beth Israel Deaconess Medical CenterScitonTerminated
-
Chulalongkorn UniversityCompletedAcne VulgarisThailand
-
Alexandria UniversityNot yet recruitingTemporomandibular DisordersEgypt
-
Second Affiliated Hospital, School of Medicine,...CompletedAcne | Atrophic ScarChina
-
Cork University HospitalFotona d.o.o.UnknownStress Urinary IncontinenceUnited Kingdom, Switzerland, Germany, Greece, Ireland, Slovenia
-
Cairo UniversityNot yet recruitingComparative Efficacy of Laser Systems and Fluoride in Managing Dentinal Hypersensitivity: RCT (DHLT)Dentin Sensitivity, Dentine Hypersensitivity, Tooth Sensitivity
-
Alma Lasers Inc.Unknown
-
Medical University of GrazCompletedLichen Planus | Lichen Sclerosus Et AtrophicusAustria
-
Instituto Vascular BHCompleted